

# Neurotech

31 July 2019

## Quarterly report for the period ending 30 June 2019

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") is pleased to present its quarterly report for the period ending 30 June 2019.

### OPERATIONAL UPDATE

In June, Neurotech launched a pilot version of Mente Clinic, a virtual clinic that enables clinicians to interact with Mente patients and remotely monitor their progress. Accessed via [www.menteclinic.com](http://www.menteclinic.com), clients can make appointments via video conferencing, and use is monitored remotely. The program is designed to enable clinicians to extend their practice, assist clients in areas where clinic access is restricted, and monitor Mente clients' progress.

Neurotech also launched an Early Adopter Program in all geographic regions where the Mente device can be used, offering discounts on Mente's Starter Pack and subscription model. Neurotech is encouraging early adopters to provide ongoing feedback on usability. Parents can also join this program, allowing them to book consultations with a Mente specialist or order the Mente headband and therapy sessions in a starter pack.

The Mente iOS application is now available to the public on the App Store. Mente clients can now choose between the iOS or Android versions of the app. This was launched during the quarter, following its beta release to users in the March quarter.

Neurotech continues to assess its assets and strategy, including the most appropriate ways to fund the ongoing operations of the Company at both the project and parent levels, with Mente as part of this consideration, following several important board changes in April.

### CORPORATE

#### BOARD & COMPANY SECRETARY APPOINTMENTS

As reported last quarter, in April, Neurotech announced several strategic appointments, with Mark Davies appointed Independent Non-Executive Chairman, Winton Willesee appointed Independent Non-Executive Director and Erlyn Dale as Company Secretary. These appointments were made in line with the Company's revised commercial strategy as it reviews Neurotech's assets to maximise shareholder value.

All three have extensive experience in helping companies in the ASX small capitalisation sector,

Concurrent with these appointments, Peter O'Connor, Simon Trevisan and Dr Neale Fong retired as directors of the Company.

#### CHANGE OF ADDRESS

During the quarter, Neurotech relocated its registered office and principal place of business. The new address and contact details are:

Suite 5 CPC  
145 Stirling Highway  
Nedlands WA 6009  
Phone: +61 8 9389 3130

Postal Address  
PO Box 3144  
Nedlands WA 6009

-ends-

---

## About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

[http:// www.neurotechinternational.com](http://www.neurotechinternational.com).

[http:// www.mentetech.com](http://www.mentetech.com).

*For more information please contact:*

Peter Griffiths

[peter.griffiths@mentetech.com](mailto:peter.griffiths@mentetech.com)

Tel: +356 99328532

---

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Neurotech International Limited

**ABN**

73 610 205 402

**Quarter ended ("current quarter")**

30 June 2019

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	3	149
1.2 Payments for		
(a) research and development	-	(72)
(b) product manufacturing and operating costs	(72)	(696)
(c) advertising and marketing	(25)	(191)
(d) leased assets	-	-
(e) staff costs	(125)	(667)
(f) administration and corporate costs	(147)	(856)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	2	8
1.5 Interest and other costs of finance paid	-	(3)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material) Wolfgang Storf severance payment	-	(169)
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(364)</b>	<b>(2,497)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	(25)
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(d) intellectual property	-	(58)
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	<b>Net cash from / (used in) investing activities</b>	-	<b>(83)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of shares	-	784
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	(49)
3.5	Proceeds from borrowings	32	94
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	<b>Net cash from / (used in) financing activities</b>	<b>32</b>	<b>829</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	805	2,212
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(364)	(2,497)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(83)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	32	829

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	2	14
4.6	<b>Cash and cash equivalents at end of quarter</b>	<b>475</b>	<b>475</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	4	14
5.2	Call deposits	471	791
5.3	Bank overdrafts (Liability)	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>475</b>	<b>805</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter  
\$A'000**

75

48

Payments to a director and their related entities for R&D consulting services, director's fees and accounting & company secretarial fees.

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

**Current quarter  
\$A'000**

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	97,099	78,335
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

The above Loan is a bank overdraft facility, with a limit of €60,000. The lender is Bank of Valetta. The facility is unsecured. The interest rate is 5.65%.

The Company classifies this facility as 'borrowings' on its annual and half yearly financial statements.


The above values are stated in AUD, converted from EUR at an exchange rate of 0.617924:1

9. <b>Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1 Research and development	-
9.2 Product manufacturing and operating costs	41
9.3 Advertising and marketing	20
9.4 Leased assets	-
9.5 Staff costs	167
9.6 Administration and corporate costs	84
9.7 Other	-
<b>9.8 Total estimated cash outflows</b>	<b>312</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	<b>Acquisitions</b>	<b>Disposals</b>
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:  .....  
(Director)

Date: ...31 July 2019.....

Print name: .....Winton Willesee.....

### Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.